New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

被引：98

作者：

Yang, Haitang ^{[1
]}

Liang, Shun-Qing ^{[1
,2
]}

Schmid, Ralph A. ^{[1
]}

Peng, Ren-Wang ^{[1
]}

机构：

[1] Univ Bern, Bern Univ Hosp, Dept Gen Thorac Surg, Dept BioMed Res,Inselspital, Bern, Switzerland

[2] Univ Massachusetts, Sch Med, Worcester, MA USA

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

lung cancer; KRAS; mitogen-activated protein kinases; heterogeneity; targeted therapy; immunotherapy; COOCCURRING GENOMIC ALTERATIONS; SELUMETINIB PLUS DOCETAXEL; PROGRESSION-FREE SURVIVAL; K-RAS; MEK INHIBITION; PHASE-II; C-RAF; MUTATION; ONCOGENE; THERAPY;

D O I：

10.3389/fonc.2019.00953

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal transition (EMT), has not only deepened our understanding about the pathobiology of KRAS-mutant NSCLC but also brought about unprecedented new hopes for precision treatment of patients. In this review, we provide an update on the most recent advances in KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRAS-mutant lung cancer.

引用

页数：13

共 103 条

[91] Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma [J].

Tolcher, Anthony W. ;

Patnaik, Amita ;

Papadopoulos, Kyriakos P. ;

Rasco, Drew W. ;

Becerra, Carlos R. ;

Allred, Alicia J. ;

Orford, Keith ;

Aktan, Gursel ;

Ferron-Brady, Geraldine ;

Ibrahim, Nageatte ;

Gauvin, Jennifer ;

Motwani, Monica ;

Cornfeld, Mark .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) :183-189

[92] T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer [J].

Tran, Eric ;

Robbins, Paul F. ;

Lu, Yong-Chen ;

Prickett, Todd D. ;

Gartner, Jared J. ;

Jia, Li ;

Pasetto, Anna ;

Zheng, Zhili ;

Ray, Satyajit ;

Groh, Eric M. ;

Kriley, Isaac R. ;

Rosenberg, Steven A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23) :2255-2262

[93] Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines [J].

Vartanian, Steffan ;

Bentley, Carolyn ;

Brauer, Matthew J. ;

Li, Li ;

Shirasawa, Senji ;

Sasazuki, Takehiko ;

Kim, Jung-Sik ;

Haverty, Pete ;

Stawiski, Eric ;

Modrusan, Zora ;

Waldman, Todd ;

Stokoe, David .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (04) :2403-2413

[94] Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function [J].

Viale, Andrea ;

Pettazzoni, Piergiorgio ;

Lyssiotis, Costas A. ;

Ying, Haoqiang ;

Sanchez, Nora ;

Marchesini, Matteo ;

Carugo, Alessandro ;

Green, Tessa ;

Seth, Sahil ;

Giuliani, Virginia ;

Kost-Alimova, Maria ;

Muller, Florian ;

Colla, Simona ;

Nezi, Luigi ;

Genovese, Giannicola ;

Deem, Angela K. ;

Kapoor, Avnish ;

Yao, Wantong ;

Brunetto, Emanuela ;

Kang, Ya'an ;

Yuan, Min ;

Asara, John M. ;

Wang, Y. Alan ;

Heffernan, Timothy P. ;

Kimmelman, Alec C. ;

Wang, Huamin ;

Fleming, Jason B. ;

Cantley, Lewis C. ;

DePinho, Ronald A. ;

Draetta, Giulio F. .

NATURE, 2014, 514 (7524) :628-+

[95] Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence [J].

Wang, Xiaojing ;

Min, Shengping ;

Liu, Hongli ;

Wu, Nan ;

Liu, Xincheng ;

Wang, Tao ;

Li, Wei ;

Shen, Yuanbing ;

Wang, Hongtao ;

Qian, Zhongqing ;

Xu, Huanbai ;

Zhao, Chengling ;

Chen, Yuqing .

EMBO MOLECULAR MEDICINE, 2019, 11 (06)

[96] Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel [J].

Wang, Zhijie ;

Duan, Jianchun ;

Cai, Shangli ;

Han, Miao ;

Dong, Hua ;

Zhao, Jun ;

Zhu, Bo ;

Wang, Shuhang ;

Zhuo, Minglei ;

Sun, Jianguo ;

Wang, Qiming ;

Bai, Hua ;

Han, Jiefei ;

Tian, Yanhua ;

Lu, Jing ;

Xu, Tongfu ;

Zhao, Xiaochen ;

Wang, Guoqiang ;

Cao, Xinkai ;

Li, Fugen ;

Wang, Dalei ;

Chen, Yuejun ;

Bai, Yuezong ;

Zhao, Jing ;

Zhao, Zhengyi ;

Zhang, Yuzi ;

Xiong, Lei ;

He, Jie ;

Gao, Shugeng ;

Wang, Jie .

JAMA ONCOLOGY, 2019, 5 (05) :696-702

[97] Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer [J].

Wiesweg, Marcel ;

Kasper, Stefan ;

Worm, Karl ;

Herold, Thomas ;

Reis, Henning ;

Sara, Linda ;

Metzenmacher, Martin ;

Abendroth, Annalena ;

Darwiche, Kaid ;

Aigner, Clemens ;

Wedemeyer, Heiner H. ;

Helfritz, Fabian A. ;

Stuschke, Martin ;

Schumacher, Brigitte ;

Markus, Peter ;

Paul, Andreas ;

Rahmann, Sven ;

Schmid, Kurt W. ;

Schuler, Martin .

ONCOGENE, 2019, 38 (16) :2953-2966

[98] Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition [J].

Wong, Gabrielle S. ;

Zhou, Jin ;

Liu, Jie Bin ;

Wu, Zhong ;

Xu, Xinsen ;

Li, Tianxia ;

Xu, David ;

Schumacher, Steven E. ;

Puschhof, Jens ;

McFarland, James ;

Zou, Charles ;

Dulak, Austin ;

Henderson, Les ;

Xu, Peng ;

O'Day, Emily ;

Rendak, Rachel ;

Liao, Wei-li ;

Cecchi, Fabiola ;

Hembrough, Todd ;

Schwartz, Sarit ;

Szeto, Christopher ;

Rustgi, Anil K. ;

Wong, Kwok-Kin ;

Diehl, J. Alan ;

Jensen, Karin ;

Graziano, Francesco ;

Ruzzo, Annamaria ;

Fereshetian, Shaunt ;

Mertins, Philipp ;

Carr, Steven A. ;

Beroukhim, Rameen ;

Nakamura, Kenichi ;

Oki, Eiji ;

Watanabe, Masayuki ;

Baba, Hideo ;

Imamura, Yu ;

Catenacci, Daniel ;

Bass, Adam J. .

NATURE MEDICINE, 2018, 24 (07) :968-+

[99] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial [J].

Wu, Yi-Long ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Li, Wei ;

Hou, Mei ;

Shi, Jian Hua ;

Lee, Kye Young ;

Xu, Chong-Rui ;

Massey, Dan ;

Kim, Miyoung ;

Shi, Yang ;

Geater, Sarayut L. .

LANCET ONCOLOGY, 2014, 15 (02) :213-222

[100] HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer [J].

Yang, Haitang ;

Liang, Shun-Qing ;

Xu, Duo ;

Yang, Zhang ;

Marti, Thomas M. ;

Gao, Yanyun ;

Kocher, Gregor J. ;

Zhao, Heng ;

Schmid, Ralph A. ;

Peng, Ren-Wang .

ONCOGENESIS, 2019, 8 (9)

← 2 3 4 5 6 7 8 9 10 11 →